Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
Open accessThe DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Abstract
Nanotechnology has brought a variety of new possibilities into biological discovery and clinical practice. In particular, nano-scaled carriers have revolutionalized drug delivery, allowing for therapeutic agents to be selectively targeted on an organ, tissue and cell specific level, also minimizing exposure of healthy tissue to drugs. In this review we discuss and analyze three issues, which are considered to be at the core of nano-scaled drug delivery systems, namely functionalization of nanocarriers, delivery to target organs and in vivo imaging. The latest developments on highly specific conjugation strategies that are used to attach biomolecules to the surface of nanoparticles (NP) are first reviewed. Besides drug carrying capabilities, the functionalization of nanocarriers also facilitate their transport to primary target organs. We highlight the leading advantage of nanocarriers, i.e. their ability to cross the blood-brain barrier (BBB), a tightly packed layer of endothelial cells surrounding the brain that prevents high-molecular weight molecules from entering the brain. The BBB has several transport molecules such as growth factors, insulin and transferrin that can potentially increase the efficiency and kinetics of brain-targeting nanocarriers. Potential treatments for common neurological disorders, such as stroke, tumours and Alzheimer's, are therefore a much sought-after application of nanomedicine. Likewise any other drug delivery system, a number of parameters need to be registered once functionalized NPs are administered, for instance their efficiency in organ-selective targeting, bioaccumulation and excretion. Finally, direct in vivo imaging of nanomaterials is an exciting recent field that can provide real-time tracking of those nanocarriers. We review a range of systems suitable for in vivo imaging and monitoring of drug delivery, with an emphasis on most recently introduced molecular imaging modalities based on optical and hybrid contrast, such as fluorescent protein tomography and multispectral optoacoustic tomography. Overall, great potential is foreseen for nanocarriers in medical diagnostics, therapeutics and molecular targeting. A proposed roadmap for ongoing and future research directions is therefore discussed in detail with emphasis on the development of novel approaches for functionalization, targeting and imaging of nano-based drug delivery systems, a cutting-edge technology poised to change the ways medicine is administered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–212 of 212
Thomas, S. A., Abbruscato, T. J., Hau, V. S., Gillespie, T. J., Zsigó, J., Hruby, V. J., & Davis, T. P. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36674-1 · Cited by 33
Increased Leptin Permeation across the Blood–Brain Barrier after Chronic Alcohol Ingestion
Pan, W., Barron, M., Hsuchou, H., Tu, H., & Kastin, A. J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301452 · Cited by 31
Distribution and analysis of surface charge on brain endothelium in vitro and in situ
dos‐Santos, W. L. C., Rahman, J., Klein, N. J., & Male, D. K. (1995) · Acta Neuropathologica · doi:10.1007/bf00296515 · Cited by 30
Murata, H., Futami, J., Kitazoe, M., Yonehara, T., Nakanishi, H., KOSAKA, M., Tada, H., Sakaguchi, M., Yagi, Y., Seno, M., et al. (2008) · The Journal of Biochemistry · doi:10.1093/jb/mvn087 · Cited by 28
Ivey, N., Martin, E. N., Scheld, W. M., & Nathan, B. R. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.07.015 · Cited by 25
Lumenta, D. B., Plesnila, N., Kläsner, B., Baethmann, A. J., Pruneau, D., Schmid-Elsaesser, R., & Zausinger, S. (2005) · Brain Research · doi:10.1016/j.brainres.2005.11.043 · Cited by 25
A novel assay for the quantification of internalized nanoparticles in macrophages
Tian, F., Tian, F., Prina‐Mello, A., Estrada, G. G., Beyerle, A., Möller, W., Schulz, H., Kreyling, W. G., & Stoeger, T. (2008) · Nanotoxicology · doi:10.1080/17435390802504229 · Cited by 23
Self-citationThe use of Pep: Trans vectors for the delivery of drugs into the central nervous system
Scherrmann, J., & Temsamani, J. (2005) · International Congress Series · doi:10.1016/j.ics.2005.02.023 · Cited by 22
The Blood-Brain Barrier and Drug Delivery to the CNS
(2000) · CRC Press eBooks · doi:10.1201/9780367800529 · Cited by 21
WITT, K. A., Huber, J. D., Egleton, R. D., & Davis, T. P. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38996-7 · Cited by 18
Ikeda, E., Takubo, K., Kodama, T., & Okada, Y. (2008) · Developmental Neuroscience · doi:10.1159/000142734 · Cited by 8
The Blood-brain Barrier and the Outer Blood-retina Barrier
Schlosshauer, B., & Steuer, H. (2005) · Medicinal Chemistry Reviews - Online · doi:10.2174/1567203052997031 · Cited by 2
Cited by
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,006
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Polymeric nanoparticles for drug delivery to the central nervous system
Patel, T., Zhou, J., Piepmeier, J. M., & Saltzman, W. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.006 · Cited by 565
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Metadata
- Authors
- Bhaskar, S., Tian, F., Stoeger, T., Kreyling, W., de la Fuente, J. M., Grazú, V., Borm, P., Estrada, G., Ntziachristos, V., & Razansky, D.
- Venue
- Particle and Fibre Toxicology
- Published
- 2010-03-03
- Volume
- 7
- Issue
- 1
- Pages
- 3-3
- ISSN
- 1743-8977 (ISSN-L)
- OpenAlex
- W2140181820
- Cited by
- 495
- References
- 212
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.